SiR-A novel vector for CRISPR delivery into the CNS
Modality Advanced therapies
Therapeutic area Neuroscience
Advantages The vector allows for a highly site specific level of infection at a very low concentration. Moreover, retrograde movement of Rabies virus means the vector could be delivered at the spinal cord or peripheral motor neurones, before tracing to a specific cell type deeper in the CNS.
Background Info A neurotropic, attenuated Rabies virus vector that can be used to deliver a payload to the CNS before self-inactivating, thereby allowing for gene editing.
Indication Central nervous system disorders
Intellectual property Granted patents and pending patent applications that entered their respective national stage from WO2018203049
Contact Elliott Jennings about this licensing opportunity
Modality Small molecules
Therapeutic area Other therapeutic area
Advantages A range of senolytic agents have been identified and validated across different cellular models of senescence. In vivo experiments in mouse models have also confirmed that some of the compounds can also eliminate senescent cells in vivo.
Background Info Senescent cells accumulate during age and are associated with many diseases. Compounds that can selectively eliminate senescent cells, so-called "senolytics", are being explored as a potential therapeutic strategy for senescence and senescence-associated diseases or disorders.
Indication Senescence and senescence-associated diseases or disorders
Intellectual property Pending patent applications that entered their respective National Stage ( EU, US,CN, JP) International Pub. No.WO2018215795A2